Stephen Brunton, MD, Director of Faculty Development, Cabarrus Family Medicine, Charlotte, North Carolina, discusses the most recent U.S. Preventive Services Task Force (USPSTF) recommendation and supporting scientific evidence on routine use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer.

Click Here to view the summary of recommendations from the USPSTF.

The Task Force grades the strength of the evidence from “A” (strongly recommends), “B” (recommends), “C” (no recommendation for or against), “D” (recommends against), or “I” (insufficient evidence to recommend for or against).

Dr. Brunton has disclosed the following:
Consulting Fees: Pfizer, Novo Nordisk, Amylin, Takeda, Novartis

Sponsored by The Doctor’s Channel